Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial - Forschungsportal der Justus-Liebig-Universität Gießen:

Meeting Abstract

Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial

Autorenliste: Kapetanovic, Meliha; Andersson, Maria; Friedman, Alan; Shaw, Tim; Song, Yanna; Aletaha, Daniel; Buch, Maya; Mueller-Ladner, Ulf; Pope, Janet

Jahr der Veröffentlichung: 2020

Seiten: 1130-1130

Zeitschrift: The Journal of Rheumatology

Bandnummer: 47

Heftnummer: 7

ISSN: 0315-162X

eISSN: 1499-2752

Konferenz: 74th Annual Meeting of the Canadian-Rheumatology-Association

Verlag: The Journal of Rheumatology

Zitierstile

Harvard-Zitierstil: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., et al. (2020) Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial, The Journal of Rheumatology, 47(7), p. 1130

APA-Zitierstil: Kapetanovic, M., Andersson, M., Friedman, A., Shaw, T., Song, Y., Aletaha, D., Buch, M., Mueller-Ladner, U., & Pope, J. (2020). Efficacy and Safety of Upadacitinib Monotherapy in MTX-Naive Patients with Early Active RA Receiving Treatment within 3 months of Diagnosis: A Post-Hoc Analysis of the SELECT-EARLY Trial. The Journal of Rheumatology. 47(7), 1130.